Asterand has extended a collaboration to give Bristol-Myers Squibb access to its products and services for up to three years.
The agreement will focus on access to Asterand's Phasezero drug-discovery services and Xpressbank of human tissue and clinical samples for the continued validation of early drug targets and support for compound optimisation.
Under the extended collaboration, Asterand will continue to undertake a range of Phasezero studies for Bristol-Myers Squibb in the areas of compound profiling and target validation.
Phasezero studies include gene and protein-expression profiling and cell-based pharmacology assays.
Likewise, Bristol-Myers Squibb will be granted access to Asterand's Xpressbank of human tissue, bio-fluid and cell lines and may also use Asterand's Procure custom clinical sample-collection service.
